Psychiatr. pro Praxi, 2007; 1: 13-16

TREATMENT OF DEPRESSION WITH ANXIETY AND INSOMNIA

MUDr. Jiřina Kosová
Psychiatrické centrum Praha, 3. LF UK, Praha

Mixed symptomatology worsens therapy compliance and response to treatment strategy, tapers off chances for achievement of full remission, increases risk of suicidal behavior. These situations thus require grounding of a different treatment plan, thinking over of additional procedures, re-evaluation of selection of drugs and their dosing. Psychotherapy and pharmacology as well, are both efficacious in treatment of isolated disorders; however combination of treatments could be more effective. This is why we strive to employ combination of remedies also in the treatment of comorbid disorders. The key aim of the treatment must be always achievement of remission. In case of unsatisfactory response to drug treatment it is advised to increase dosage up to the most tolerated level, than replacement of treatment or combination. It is essential that medication must be given minimally for period of one year. Inhibitors of reuptake of serotonine (SSRI) and inhibitors of reuptake of serotonine and noradrenaline (SNRI) are usually chosen as the first line treatment because of their efficacy and relative benign safety profile; however they may not always be treatment of choice for each comorbid patient. CBT is at least as effective as SSRIs and SNRIs, in addition is having usually longer lasting effect after its completion, thus can be successful in these difficult-to-treat patients.

Keywords: treatment of comorbid depressive, anxiety disorders, and insomnia, pharmacotherapy, cognitive-behavioral therapy

Published: January 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kosová J. TREATMENT OF DEPRESSION WITH ANXIETY AND INSOMNIA. Psychiatr. praxi. 2007;8(1):13-16.
Download citation

References

  1. Adson DE, Kushner MG, Fahnhorst TA. Treatment of residual anxiety symptoms with adjunctive aripiprazole in depressed patients taking selective serotonin reuptake inhibitors. J Affect Disord 2005; 86 (1): 99-104. Go to original source... Go to PubMed...
  2. Alpert JE, Franznick DA, Hollander SB, Fava M. Gepirone extended-release treatment of anxious depression: evidence from retrospective subgroup analysis in patients with major depressive disorder. J Clin Psychiatry 2004; 65 (8): 1069-1075. Go to original source... Go to PubMed...
  3. Baldwin DS. Serotonin noradrenaline reuptake inhibitors: A new generation of treatment for anxiety disorders. Int J Psychiatry Clin Pract 2006; 10 (Suppl. 2): 12-15. Go to original source... Go to PubMed...
  4. Belzer K, Schneier FR. Comorbidity of anxiety and depressive disorders: Issues in conceptualization, assessment, and treatment. J Psych Practice 2004; 10 (5): 296-306. Go to original source... Go to PubMed...
  5. Benca RM. Diagnosis and treatment of chronic insomnia: A review. Psych Services 2005; 56 (3): 332-343. Go to original source... Go to PubMed...
  6. Bielski RJ, Ventura D, Chang CC. A double-blind comparison of ecitalopram and venlafaxine extended-release in the treatment of major depressive disorder. J Clin Psychiatry 2005; 65: 1190-1196. Go to original source... Go to PubMed...
  7. Carpenter LL, Schecter JM, Tyrka AR, et al. Open-label tiagabine monotherapy for major depressive disorder with anxiety. J Clin Psychiatry 2006; 67 (1): 66-71. Go to original source... Go to PubMed...
  8. Den Boer JA, Bosker FJ, Meesters Y. Clinical efficacy of agomelatine in depression: the evidence. Int Clin Psychopharmacol 2006; 21 (Suppl 1): S21-S24. Go to original source... Go to PubMed...
  9. Dubochovich ML. Agomelatine targets a range of major depressive disorder symptoms. Curr Opin Investig Drugs 2006; 7 (7): 670-680. Go to PubMed...
  10. Dugas MJ, Ladouceur R, Leger E, et al. Group cognitive-behavioral therapy for generalized anxiety disorder: treatment outcome and long-term follow-up. J Consult Clin Psychol 2003; 71 (4): 821-825. Go to original source... Go to PubMed...
  11. Fawcett J, Marcus RN, Anton SF, et al. Response of anxiety and agitation symptoms during nefazodone treatment of major depression. J Clin Psychol 1995; 56: 37-42.
  12. Galynker I, Khan A, Grebchenko Y, et al. Low-dose risperidone and quetiapine as monotherapy for comorbid anxiety and depression. J Clin Psychiatry 2005; 66 (4): 544. Go to original source... Go to PubMed...
  13. Hollon SD, Stewart MO, Strunk D. Enduring effects for cognitive behavior therapy in the treatment of depression and anxiety. An Rev Psychology 2006; 57: 285-315. Go to original source... Go to PubMed...
  14. Joliat MJ, Schmidt ME, Fava M, et al. Long-term treatment outcomes of depression with associated anxiety: efficacy of continuation treatment with fluoxetine. J Clin Psychiatry 2004; 65 (3): 373-378. Go to original source... Go to PubMed...
  15. Keller MB. Efficacy of nefazodone in chronic depression. J Clin Psychol 2002; 63: 24-27.
  16. Kocsis JH, Rush AJ, Markowitz JC, et al. Continuation treatment of chronic depression; a comparison of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination. Psychopharmacol Bull 2003; 37 (4): 73-87. Go to PubMed...
  17. Lam RW. Sleep disturbances and depression: a challenge for antidepressants. Int Clin Psychopharm 2006; 21 (Suppl. 1): S25-S29. Go to original source... Go to PubMed...
  18. Lemoine P, Faivre T. Subjective and polysomnographic effects of minlacipran on sleep in depressed patients. Hum Psychopharmacol 2004; 19 (5): 299-303. Go to original source... Go to PubMed...
  19. Maršálek M. Antidepresiva a architektura spánku u velké deprese. Psychiatrie pro praxi 2005; 3: 128-132.
  20. McGechan A, Wellington K. Ramelteon. CNS Drugs 2005; 19 (12): 1057-1065. Go to original source... Go to PubMed...
  21. Montgomery SA, Tobias K, Zornberg GL, et al. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebocontrolled comparison of pregabalin and venlafaxine. J Clin Psychiatry 2006; 67 (5): 771-782. Go to original source... Go to PubMed...
  22. Nemeroff CB. Use of atypical antopsychotics in refractory depression and anxiety. J Clin Psychiatry 2005; 66 (Suppl.8): 13-21.
  23. Nierenberg AA, Wright EC. Evolution of remission as the new standard in the treatment of depression. J Clin Psychiatry 1999; 60 (suppl 22): 7-11.
  24. Ninan PT, Berger J. Symptomatic and syndromal anxiety and depression. Depress Anxiety 2001; 14 (2): 79-85. Go to original source... Go to PubMed...
  25. Ninan PT, Rush AJ, Crits-Christoph P, et al. Symptomatic and syndromal anxiety in chronic forms of major deporession: effect of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination. J Clin Psychiatry 2002; 63 (5): 434-441. Go to original source... Go to PubMed...
  26. Pande AC, Pollack MH, Crockatt J, et al. Placebo-controlled study of gabapentin treatment of panic disorder. Clin Psychopharmacol 2000; 20: 467-471. Go to original source... Go to PubMed...
  27. Panzer MJ. Are SSRIs really more effective for anxious depression? Ann Clin Psychiatry 2005; 17 (1): 23-29. Go to original source... Go to PubMed...
  28. Paxil CR(R) (package insert). Research Triangle Park, NC: GlaxoSmithKline; 2005.
  29. Pini S, Amador XF, Dell´Osso L, et al. Treatment of depression with comorbid anxiety disorders: differebtial efficacy of paroxetine versus moclobemide. Int Clin Psychopharmacol 2003; 18 (1): 15-21. Go to original source... Go to PubMed...
  30. Pollack MH. Comorbid anxiety and depression. J Clin Psychiatry 2005; 66 (Suppl.8): 22-29.
  31. Provencher MD, Ladouceur R, Dugas MJ. Comorbidity in generalized anxiety disorder: Prevalence and course after cognitive-behavioural therapy. Can J Psychiatry 2006; 51 (2): 91-99. Go to original source... Go to PubMed...
  32. Rosenberg RP. Sleep maintenance insomnia: strengths and weaknesses of current pharmacologic therapies. Ann Clin Psychiatry 2006; 18 (1): 49-56. Go to original source... Go to PubMed...
  33. Rosenthal M. Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control. J Clin Psychiatry 2003; 64 (10): 1245-1249. Go to original source... Go to PubMed...
  34. Rouillon F. Efficacy and tolerance profile of agomelatine and practical use in depressed patients. int Clin Psychopharmacol 2006; 21 (Suppl 1): S31-S35. Go to original source... Go to PubMed...
  35. Roy-Byrne PP, Craske MG, Stein MB, et al. A randomized effectiveness trial of cognitive-behavioral therapy and medication for primary care panic disorder. Arch Gen Psychiatry 2005; 62 (3): 290-298. Go to original source... Go to PubMed...
  36. Schatzberg AF, Rush AJ, Arnow BA, et al. Chronic depression: medication (nefazodone) or psychotherapy (CBASP) is effective when the other is not. Arch Gen Psychiatry 2005; 62 (5): 513-520. Go to original source... Go to PubMed...
  37. Švestka J. Nová psychofarmaka: Mirtazapin, noradrenergní a specificky serotonergní antidepresívum. Psychiatrie 1999; 4: 248-258.
  38. Švestka J. Escitalopram - selektivní stereoizomer citalopramu. Psychiatrie 2003; 7(1): 38-45.
  39. Švestka J. Agomelatin - nové melatonergní a serotonergní antidepresivum. Psychiatrie 2005; 9 (4): 307-310.
  40. Thase ME. Antidepressant treatment of the depressed patiens with insomnia. J Clin Psychiatry 1999; 60 (Suppl 17): 28-31.
  41. Thase ME. Treatment issues related to sleep and depression. J Clin Psychiatry 2000; 61 (Suppl. 11): 46-50.
  42. Thase ME, Rush AJ, Manber R, et al. Differential effects of nefazodone and cognitive behavioral analysis system of psychotherapy on insomnia associated with chronic forms of major depression. J Clin Psychiatry 2002; 63 (6): 493-500. Go to original source... Go to PubMed...
  43. Van Ameringen M, Mancini C, Pipe B, et al. Antiepileptic drugs in the treatment of anxiety disorders: role in therapy. Drugs 2004; 64 (19): 2199-2220. Go to original source... Go to PubMed...
  44. Ware JC. Tricyclic antidepressants in the treatment of insomnia. J Clin Psychiatry 1983; 44 (9 Pt 2): 25-28.
  45. Worthington JJ, Kinrys G, Wygant LE, et al. Aripiprazole as augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients. Int Clin Psychopharmacol 2005; 20 (1): 9-11. Go to original source... Go to PubMed...
  46. Zajecka JM. The effect of nefazodone on comorbid anxiety symptoms associated with depression: experience in family practice and psychiatric outpatients settings. J Clin Psychiatry 1996; 57 (Suppl.2): 10-14.
  47. Závěšická L. Antidepresiva a hypnotika III. generace v léčbě chronické nespavosti. Psychiat pro Praxi 2006; 4: 174-175.




Psychiatry for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.